PTC Therapeutics Inc (STU:BH3)
€ 36.8 0 (0%) Market Cap: 2.89 Bil Enterprise Value: 2.25 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

PTC Therapeutics Inc at Barclays Virtual Gene Editing & Gene Therapy Summit Transcript

Nov 16, 2020 / 08:30PM GMT
Release Date Price: €50.5 (+1.00%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon, everyone. My name is Gena Wang. I'm a SMid-Cap Biotech analyst at the Barclays. It is my great pleasure to introduce our next presenting company, PTC Therapeutics. On the screen, on the Zoom with me, we have Matt Klein, Chief Development Officer. Also, we have Lisa Hayes, VP of Investor Relations.

With that, I hand over to Matt to give a slide presentation.

Matthew B. Klein
PTC Therapeutics, Inc. - Chief Development Officer

Thank you very much, Gena. It's great to have this opportunity to share an update on PTC's many exciting activities. This presentation will contain forward-looking statements.

For those of you who don't know PTC, we are a global commercial, diversified biopharmaceutical company focused on discovering, developing and commercializing innovative therapies to treat rare disorders.

PTC started in New Jersey 22 years ago as a small science-based company. And over the past few decades, we have built a robust global research,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot